Dr. Michael Silverman of BioStrategics Consulting Ltd. discusses some of the dilemmas associated with Phase 1 clinical trial design and implementation in the field of oncology and the impact on drug development.
Many of you are familiar with Phase 1 clinical trials in oncology. For decades, the Standard Design the “3 +3″ trial Leg (always in the patient) to the establishment security profile, dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of a new anti-cancer
No comments:
Post a Comment